A large number of studies demonstrated that enhanced expression of cyclin B1 in tumor tissue was associated with poor survival of patients with various types of solid tumors such as breast cancer [21, 22], lung cancer [10, 23–25], esophageal cancer [26–28], gastric cancer [15], hepatocellular carcinoma [16], pancreatic cancer [12, 29], embryonal tumors [30], and laryngeal carcinoma [13]. Here, CCNB1 is linked to neoplasm.